Table 3

Unit costs

Parameter	Base case value (£)^*	Range of variation in sensitivity analysis	Basis of variation; distribution type in PSA
Drug costs20
Abciximab (ReoPro) 10 mg phial	250	–^†	NA
Eptifibatide (Integrilin) 20 mg; 75 mg phial	14; 43	–^†
Tirofiban (Aggrastat) 12.5 mg phial	161	–^†
Bivalirudin (Angiomax) 250 mg phial	310	–^†
Event and procedure costs
Angiography procedure cost^‡ 21	283	269–501	IQR; triangular
PCI cost22	3152	2278–3865
PCI procedure cost^‡ 22 23	1733	1253–2126
CABG cost22	8372	6690–9707
CABG procedure cost^‡ 22 24	3115	2489–3611
Q-wave MI22	1746	1291–2011
Non-Q-wave MI22 25	541	400–623
Ischaemic stroke cost26	10611	5306–15 917	±50%; uniform
Ischaemic stroke non-ward cost^‡ 22 26	8873	4436–13 309
Major bleed cost22 27	2364	1182–3545
Major bleed non-ward cost^‡ 22 27	1300	650–1950
Minor bleed cost22 27	144	72–216
Minor bleed non-ward cost^‡ 22 27	79	40–119
Ward costs
Normal ward day28	274	–^§	NA
CCU/ICU day22	814^¶	–^§
Long-term annual cardiovascular treatment cost of 1-year or 3-year survivors^** 29	900	450–1350	±50%; uniform

↵* Unit costs at 2009–2010 prices. Inflated from older values where required.30
↵† Unit costs of anticoagulant phials were not varied as they were not subject to parameter uncertainty.
↵‡ Excluding ward costs.
↵§ Not varied in sensitivity analysis as variation of length of stay in the comparator strategy was assumed to also cover uncertainty in these unit cost estimates.
↵¶ Simple average of NHS reference costs for intensive care unit and coronary care unit. See online supplement.
↵** Also used to represent annual cardiovascular outpatient treatment and drug costs in year 1 (years 1–3, in the alternative model).
HRG, Healthcare Resource Group; ICU/CCU, intensive care unit/coronary care unit; NA, not applicable; NHS, National Health Service; PSA, probabilistic sensitivity analysis.